

Amaxa™ 4D-Nucleofector™ Basic Protocol for Primary Mammalian Smooth Muscle Cells For 4D-Nucleofector™ X Unit—Transfection in suspension

Cells derived from mammalian smooth muscle cell tissues from various organs; adherent long tapering cells

Note

Mammalian smooth muscle cells display significant phenotypic variations due to the wide range of both species and tissues from which they may be sourced.

This basic protocol describes how to easily define optimal Nucleofection™ Conditions for different mammalian smooth muscle cells. We recommend to first test a set of pre-selected Nucleofector™ Programs together with the P1 Primary Cell 4D-Nucleofector™ X Kit.

For highest convenience of the initial optimization step we recommend using the 16-well Nucleocuvette™ Strip format. Determined conditions are transferable to the 100 µl single Nucleocuvette™. However, you may also directly perform the optimization with the 100 µl single Nucleocuvette™ Format.

If you have questions regarding your epithelial cells of interest, please contact our Scientific Support Team for further help with the optimization.

Product Description

Recommended Kit(s)—P1 Primary Cell 4D-Nucleofector™ X Kit

Cat. No.	V4XP-1012	V4XP-1024	V4XP-1032
Transfection volume	100 µl	100 µl	20 µl
Size [reaction]	2 x 6	24	2 x 16
Nucleofector™ Solution	2 x 0.675 ml (0.492 ml + 27% overfill)	2.25 ml (1.968 ml + 13% overfill)	0.675 ml (0.525 ml + 22% overfill)
Supplement	2 x 0.15 ml (0.108 ml + 27% overfill)	0.5 ml (0.432 ml + 13% overfill)	0.15 ml (0.115 ml + 22% overfill)
pmaxGFP™ Vector (1 µg/µl in 10 mM Tris pH 8.0)	50 µg	50 µg	-
Single Nucleocuvette® (100 µl)	12	24	-
16-well Nucleocuvette™ Strips (20 µl)	-	-	2

Storage and stability

Store Nucleofector™ Solution, Supplement and pmaxGFP™ Vector at 4 °C. For long-term storage, pmaxGFP™ Vector is ideally stored at -20 °C. The expiration date is printed on the solution box. Once the Nucleofector™ Supplement is added to the Nucleofector™ Solution, it is stable for three months at 4 °C.

Note

4D-Nucleofector™ Solutions could be only used with Nucleocuvettes™ (conductive polymer cuvettes), i.e. in the 4D-Nucleofector™ System and the 96-well Shuttle™ Device. They are not compatible with the Nucleofector™ II/2b Device.

Optimization Guidelines

The initial optimization experiment is comprised of 14 reactions, using 6 different Nucleofector™ Programs plus 1 control tested in duplicate. The program which turns out to be the most appropriate Nucleofection™ Condition should be used for all subsequent transfections. A further fine tuning of the Nucleofection™ Condition can be performed with the help of our Scientific Support Team.

Nucleocuvette™ Strip 1: P1 Solution

	1	2
A	FF-130	FF-130
B	FG-113	FG-113
C	DS-137	DS-137
D	CM-137	CM-137
E	EH-106	EH-106
F	FP-113	FP-113
G	Negative control (no program)	Negative control (no program)
H		

The P1 Primary Cell 4D-Nucleofector™ Solution has been tested successfully for the following Clonetics™ Primary Cells provided by Lonza:

Cell type	Lonza Cat. No.	Optimal Program	Transfection efficiency	Viability*
AoSMC (Human Aortic Smooth Muscle Cells)	CC-2571	EH-106	74 %	92 %
CASMC (Human Coronary Artery Smooth Muscle Cells)	CC-2583	FP-113	67 %	86 %
PASMC (Human Pulmonary Artery Smooth Muscle Cells)	CC-2581	FG-113	81 %	67 %

*Determined by ViaLight™ Plus Kit, Lonza

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector™ Solution. The ratio of Nucleofector™ Solution to supplement is 4.5 : 1 (see table 1)

- 4D-Nucleofector™ System (4D-Nucleofector™ Core Unit and 4D-Nucleofector™ X Unit)
- Supplemented 4D-Nucleofector™ Solution at room temperature
- Supplied 100 µl single Nucleocuvette™ or 20 µl 16-well Nucleocuvette™ Strips
- **Compatible tips for 20 µl Nucleocuvette™ Strips:** epT.I.P.S. [US/CDN: Eppendorf North America, Cat. No. 2491.431, Rest of World: Eppendorf AG, Cat. No. 0030073.266], Matrix TallTips® [Matrix Technologies Corp., Cat. No. 7281] or LTS Tips [Rainin Instruments, LLC, Cat. No. SR-L10F, SR/SS-L250S, SR/SS-L300S]. Before using other types of pipette tips, please ensure they reach the bottom of the Nucleocuvette™ Wells without getting stuck
- **Supplied pmaxGFP™ Vector, stock solution 1 µg/µl**

Note

For positive control using pmaxGFP™, dilute the stock solution to an appropriate working concentration. Further details are provided in table 3 of this Optimized Protocol. The volume of substrate solution added to each sample should not exceed 10% of the total reaction volume (2 µl for 20 µl reactions; 10 µl for 100 µl reactions).

- Substrate of interest, highly purified, preferably by using endotoxin-free kits; A260 : A280 ratio should be at least 1.8
- Cell culture plates of your choice
- **For detaching cells:** Please use trypsin as recommended by the cell supplier e.g. ReagentPack™ Subculture Reagent Kit containing Trypsin/EDTA, HEPES Buffered Saline Solution (HEPES-BSS) and Trypsin Neutralizing Solution (TNS) [Lonza; Cat. No. CC-5034]
- **Culture medium:** Please use media as recommended by the cell supplier e.g. SmGM®-2 BulletKit™ [Lonza; Cat. No. CC-3182]
- Prewarm appropriate volume of culture medium to 37 °C (see table 2)
- Appropriate number of cells/sample (see table 2)

1. Pre Nucleofection™

Notes

1. Transfection results may be cell-source dependent.
2. Culture conditions may differ between cell types. Please follow your established procedure or the supplier's recommendations.

Cell culture recommendations

- 1.1 Replace medium every 1–3 days
- 1.2 Cells should be passaged after reaching 70–80 % confluency
- 1.3 Do not use cells after passage 9 for Nucleofection™ as this may lead to reduced viability and transfection efficiency
- 1.4 Cells should be passaged 2–4 days before Nucleofection™ depending on growth rate of cells

Trypsinization

Note

Please follow your established procedure or the supplier's recommendations (e.g. for Aortic Smooth Muscle Cells [Lonza; Cat. No. CC-2571] follow procedure described below).

- 1.5 Remove media from the cultured cells and wash cells once with HEPES-BSS
- 1.6 For harvesting, incubate the cells ~5 minutes at 37 °C with recommended volume of indicated trypsinization reagent (please see required material)
- 1.7 Inactivate trypsin with TNS once the majority of the cells (>90 %) have been detached

2. Nucleofection™

For Nucleofection™ Sample contents and recommended Nucleofector™ Program, please refer to Table 3.

- 2.1 Please make sure that the entire supplement is added to the Nucleofector™ Solution
- 2.2 Start 4D-Nucleofector™ System and create or upload experimental parameter file (for details see device manual)
- 2.3 Select/Check for the appropriate Nucleofector™ Program (see table 3)
- 2.4 Prepare cell culture plates by filling appropriate number of wells with desired volume of recommended culture media (see table 4) and pre-incubate/equilibrate plates in a humidified 37 °C/5 % CO₂ incubator
- 2.5 Pre-warm an aliquot of culture medium to 37 °C (see table 4)
- 2.6 Prepare plasmid DNA or pmaxGFP™ Vector or siRNA (see table 3)
- 2.7 Harvest the cells by trypsinization (please see 1.5–1.7)
- 2.8 Count an aliquot of the cells and determine cell density
- 2.9 Centrifuge the required number of cells (see table 3) at 100xg for 10 minutes at room temperature. Remove supernatant completely
- 2.10 Resuspend the cell pellet carefully in room temperature 4D-Nucleofector™ Solution (see table 3)
- 2.11 Prepare mastermixes by dividing cell suspension according to number of substrates

- 2.12 Add required amount of substrates to each aliquot (max. 10 % of final sample volume)
- 2.13 Transfer mastermixes into the Nucleocuvette™ Vessels

Note

As leaving cells in Nucleofector™ Solution for extended periods of time may lead to reduced transfection efficiency and viability it is important to work as quickly as possible. Avoid air bubbles while pipetting.

- 2.14 Gently tap the Nucleocuvette™ Vessels to make sure the sample covers the bottom of the cuvette
- 2.15 Place Nucleocuvette™ Vessel with closed lid into the retainer of the 4D-Nucleofector™ X Unit. Check for proper orientation of the Nucleocuvette™ Vessel
- 2.16 Start Nucleofection™ Process by pressing the "Start" on the display of the 4D-Nucleofector™ Core Unit (for details, please refer to the device manual)
- 2.17 After run completion, carefully remove the Nucleocuvette™ Vessel from the retainer
- 2.18 Resuspend cells with pre-warmed medium (for recommended volumes see table 5). Mix cells by gently pipetting up and down two to three times. When working with the 100 µl Nucleocuvette™ use the supplied pipettes and avoid repeated aspiration of the sample
- 2.19 Plate desired amount of cells in culture system of your choice (for recommended volumes see table 5)

3. Post Nucleofection™

- 3.1 Incubate the plating cells in a humidified 37 °C/5 % CO₂ incubator until analysis. Gene expression or down-regulation, is often detectable after only 4–8 hours. To validate optimal conditions for down regulation we recommend performing a time course experiment

Additional Information

For an up-to-date list of all Nucleofector™ References, please refer to:

www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA /Canada

Phone: 800 521 0390 (toll-free)

Fax: 301 845 8338

E-mail: scientific.support@lonza.com

Europe and Rest of World

Phone: +49 221 99199 400

Fax: +49 221 99199 499

E-mail: scientific.support.eu@lonza.com

Lonza Cologne GmbH 50829 Cologne, Germany

Please note that the Amaxa™ Nucleofector™ Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans.

The Nucleofector™ Technology, comprising Nucleofection™ Process, Nucleofector™ Device, Nucleofector™ Solutions, Nucleofector™ 96-well Shuttle™ System and 96-well Nucleocuvette™ plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne GmbH.

Amaxa, Nucleofector, Nucleofection, 4D-Nucleofector, 96-well Shuttle, Nucleocuvette, maxGFP, Clonetics, Reagent Pack, SmGM and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com. The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2010, Lonza Cologne GmbH. All rights reserved.

Table 1: Volumes required for a single reaction

	100 µl Single Nucleocuvette™	20 µl Nucleocuvette™ Strip
Volume of Nucleofector™ Solution	82 µl	16.4 µl
Volume of Supplement	18 µl	3.6 µl

Table 2: Required amounts of cells and media for Nucleofection™

	100 µl Single Nucleocuvette™	20 µl Nucleocuvette™ Strip
Culture medium per sample post Nucleofection™ (for transfer and culture)	1.5 ml	160 µl
Cell number per Nucleofection™ Sample	0.5–1 x 10 ⁶ cells Minimal cell number: 2 x 10 ⁵ cells, a lower cell number may lead to a major increase in cell mortality; maximal cell number: 2 x 10 ⁶ cells)	1 x 10 ⁵ cells (Minimal cell number: 5 x 10 ⁴ cells, a lower cell number may lead to a major increase in cell mortality)

Table 3: Contents of one Nucleofection™ Sample and recommended program

	100 µl Single Nucleocuvette™	20 µl Nucleocuvette™ Strip
Cells	0.5–1 x 10 ⁶	1 x 10 ⁵
Substrate*	pmaxGFP™ Vector	2 µg
	or plasmid DNA (in H ₂ O or TE)	1–5 µg
	or siRNA	30–300nM siRNA (3–30 pmol/sample)
P3 Primary Cell 4D-Nucleofector™ Solution	100 µl	20 µl
Program	FF-130 or FG-113 or DS-137 or CM-137 or EH-106 or FP-113	FF-130 or FG-113 or DS-137 or CM-137 or EH-106 or FP-113

* Volume of substrate should comprise maximum 10% of total reaction volume

Table 4: Culture volumes required for post Nucleofection™ Steps

	100 µl Single Nucleocuvette™	20 µl Nucleocuvette™ Strip*
6-well culture plate	1 ml	-
96-well culture plate	-	80 µl
Culture medium to be added to the sample post Nucleofection™	500 µl	80 µl

* Maximum cuvette volume 200 µl

Table 5: Recommended volumes for sample transfer into culture plate

	100 µl Single Nucleocuvette™	20 µl Nucleocuvette™ Strip*
Culture medium to be added to the sample post Nucleofection™	500 µl	80 µl
Volume of sample transferred to culture plate	complete sample (use supplied pipettes)	20 µl

* Maximum cuvette volume 200 µl